

PRESS RELEASE

IDOGEN AB



Org no. 556756-8521

Date: November 28 2018

Idogen demonstrates proof-of-principle in a model of autoimmune disease

Idogen has, as previously announced, decided to evaluate the potential of the company's technology in a group of autoimmune diseases where there is a high unmet medical need and where the treatment could be granted orphan drug designation. The company has now successfully completed a pre-clinical study in a model of autoimmune uveitis, a serious disease which can lead to blindness.

In the model of induced autoimmune uveitis, groups of animals were treated with zebularine by injection. The group of animals treated with zebularine showed a significant positive effect in symptom relief compared with the control group of untreated animals. The model is T cell driven and the effect of zebularine is therefore expected to be relevant to the treatment of additional autoimmune diseases.

"This study is an important step in the evaluation of a number of autoimmune diseases that we are now conducting and it is positive that we are able to achieve these results. The results represent an important piece of the puzzle in our analysis and will be compared with the additional work that is carried out in other autoimmune diseases and with other methods of administration" – CEO Lars Hedbys comments.

For additional information, please contact:

Lars Hedbys, CEO Idogen AB

Tel: +46 (0)46-275 63 30

E-mail: lars.hedbys@idogen.com

This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU's Market Abuse Regulation. The information was submitted for publication through the above contact person on the 28th of November 2018.

Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. Idogen's most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company's second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com